In a patient undergoing treatment for multiple myeloma who has type 2 diabetes mellitus, are oral antidiabetic agents appropriate?

Oral Diabetes Medications in Multiple Myeloma Patients

Yes, oral diabetes medications are appropriate for patients with type 2 diabetes undergoing multiple myeloma treatment, with metformin as the preferred first-line agent, though careful monitoring for hyperglycemia and treatment adjustments are essential due to corticosteroid use in myeloma therapy. 1

First-Line Oral Agent Selection

Metformin should be prescribed as the initial oral antidiabetic agent for most patients with type 2 diabetes and multiple myeloma, unless contraindicated 1. Metformin offers several advantages in this population:

• Reduces HbA1c by 0.7-1.0% without causing hypoglycemia when used alone 2
• Does not cause weight gain and may actually promote weight loss, which is beneficial given that corticosteroids used in myeloma treatment promote weight gain 1
• Improves lipid profiles by decreasing LDL cholesterol and triglycerides 1
• Associated with improved survival outcomes in diabetic myeloma patients, with one study showing metformin predicted increased overall survival in diabetic MM patients 3

Metformin Contraindications in Myeloma Patients

Metformin is contraindicated in several situations common to myeloma patients 1, 2:

• Renal impairment: serum creatinine >132.6 μmol/L (1.5 mg/dL) in men or >123.8 μmol/L (1.4 mg/dL) in women, or eGFR <45 mL/min/1.73m² 2
• Reduce metformin dose if eGFR is 45-59 mL/min/1.73m² 2
• Temporarily discontinue before iodinated contrast procedures (relevant for skeletal surveys and staging imaging) 2
• Liver dysfunction, severe infection, or hypoxia 2

This is particularly important because 12.9% of newly diagnosed myeloma patients have pre-existing diabetes, and these patients have significantly higher rates of renal impairment at diagnosis 4.

Second-Line Oral Agents

When metformin monotherapy fails to achieve glycemic targets, add a second oral agent 1:

Sulfonylureas

• Reduce HbA1c by 1.0-1.5% 2
• Major risk: hypoglycemia, especially when combined with corticosteroids 1
• Use gliquidone in patients with mild renal insufficiency 2
• Avoid in patients with significant renal impairment (common in myeloma) 2

DPP-4 Inhibitors

• Moderate efficacy with low side-effect profile 5
• Low risk of hypoglycemia 5
• Good option when metformin causes gastrointestinal side effects or when sulfonylureas cause significant hypoglycemia 5
• Use with caution if lipase is elevated (relevant given pancreatitis risk with some myeloma treatments) 6

Thiazolidinediones (TZDs)

• Reduce HbA1c by 0.7-1.0% 2
• Do not cause hypoglycemia when used alone 2
• Major concerns: weight gain, edema, and increased risk of heart failure 1
• Increased bone fracture risk, particularly in women (HR 1.81 for women) 1, which is problematic given myeloma-related bone disease 7, 8

Critical Management Considerations for Myeloma Patients

Steroid-Induced Hyperglycemia

Corticosteroids are a cornerstone of myeloma treatment (used in VAD regimens, with melphalan-prednisone, and with novel agents) 7, 8, creating unique challenges:

• Steroid-induced diabetes (SID) is a significant predictor of decreased overall survival in myeloma patients 3
• Manage mild steroid-induced hyperglycemia with oral agents such as gliclazide and metformin 6
• DPP-4 inhibitors or GLP-1 receptor agonists are appropriate second-line therapy if pancreatitis and elevated lipase are absent 6
• Moderate to severe cases require insulin therapy matched to the steroid dose and profile 6

Insulin Use Warning

Avoid insulin when possible in diabetic myeloma patients, as research shows:

• Insulin/insulin analogues are associated with decreased overall survival in diabetic MM patients 3
• Insulin use predicted increased death with progressive myeloma in multivariate analysis 3
• Insulin is associated with increased dementia risk in type 2 diabetes patients 9

Monitoring Requirements

Implement intensive glucose monitoring during myeloma treatment 10:

• Daily patient self-monitoring of capillary blood glucose for high-risk patients (newly detected hyperglycemia, pre-existing diabetes, commencing corticosteroids) 6
• Monitor serum glucose 2 hours postprandial or 8 hours after prednisolone dosing (fasting levels will not capture severity of steroid-induced hyperglycemia) 6
• Check for ketones capability in high-risk patients 6

Common Pitfalls to Avoid

1. Do not continue metformin in patients with declining renal function, as myeloma commonly causes renal impairment and cast nephropathy 7, 8, 4

2. Do not use thiazolidinediones in patients with heart failure or significant bone disease, both common in myeloma 1

3. Do not rely on fasting glucose alone when patients are on corticosteroids—postprandial or timed glucose measurements are essential 6

4. Do not overlook the need for treatment adjustment as 29.4% of diabetic myeloma patients require changes in antidiabetic therapy during disease course 4

5. Do not use GLP-1 receptor agonists or DPP-4 inhibitors if lipase is elevated, as these can rarely cause pancreatitis 6

Treatment Algorithm Summary

For newly diagnosed or stable myeloma patients with type 2 diabetes:

1. Start metformin if eGFR ≥45 mL/min/1.73m² and no other contraindications 1
2. If metformin contraindicated or insufficient, add DPP-4 inhibitor (preferred) or sulfonylurea (if cost is concern) 1, 5
3. If starting corticosteroids, intensify glucose monitoring and consider adding gliclazide 6
4. Reserve insulin for severe hyperglycemia or when oral agents fail, given association with worse outcomes 3
5. Adjust or discontinue metformin if renal function deteriorates (monitor closely as myeloma progresses) 2